开云app官网登录入口网页版-官方正版

#CHB#

16篇内容 | 1158人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1460262, encodeId=8409146026218, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=Hepatology：乙肝纳米疫苗εPA-44可明显提高CHB患者的HBeAg血清学转换率, objectType=article, longId=215974, objectId=5cf22159e493, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cf22159e493, replyNumber=0, likeNumber=0, createdTime=2021-08-20, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cf22159e493, moduleTitle=Hepatology：乙肝纳米疫苗εPA-44可明显提高CHB患者的HBeAg血清学转换率, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5cf22159e493)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460261, encodeId=58721460261bd, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=J Hepatol：长期恩替卡韦/替诺福韦治疗CHB 生存率影响几何？, objectType=article, longId=141768, objectId=a500141e68d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a500141e68d7, replyNumber=0, likeNumber=62, createdTime=2018-06-29, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a500141e68d7, moduleTitle=J Hepatol：长期恩替卡韦/替诺福韦治疗CHB 生存率影响几何？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a500141e68d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460260, encodeId=1422146026024, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=Liver Int：在埃塞俄比亚CHB患者中，HDV感染很少见，但与更严重的肝纤维化相关, objectType=article, longId=141574, objectId=3eab1415e47a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eab1415e47a, replyNumber=0, likeNumber=0, createdTime=2018-06-26, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eab1415e47a, moduleTitle=Liver Int：在埃塞俄比亚CHB患者中，HDV感染很少见，但与更严重的肝纤维化相关, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3eab1415e47a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460259, encodeId=a17014602592a, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=Hepatol Res：在日本CHB患者中，早期从恩替卡韦治疗转换到聚乙二醇干扰素的序贯治疗，结果并不令人满意, objectType=article, longId=140003, objectId=fbd714000360, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbd714000360, replyNumber=0, likeNumber=63, createdTime=2018-06-06, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbd714000360, moduleTitle=Hepatol Res：在日本CHB患者中，早期从恩替卡韦治疗转换到聚乙二醇干扰素的序贯治疗，结果并不令人满意, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fbd714000360)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460258, encodeId=5c5b146025873, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=J Hepatol：接受核苷酸类似物治疗的CHB患者中，治疗后血清ALT达到正常水平，可较少肝脏相关事件。, objectType=article, longId=138577, objectId=2f4b1385e7e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f4b1385e7e0, replyNumber=0, likeNumber=106, createdTime=2018-05-20, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f4b1385e7e0, moduleTitle=J Hepatol：接受核苷酸类似物治疗的CHB患者中，治疗后血清ALT达到正常水平，可较少肝脏相关事件。, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2f4b1385e7e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460257, encodeId=64a2146025e70, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=J Viral Hepat：相比APRI和FIB-4，GPR在预测CHB患者肝纤维化不同程度方面表现更佳, objectType=article, longId=137952, objectId=fa0613e952f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa0613e952f4, replyNumber=0, likeNumber=66, createdTime=2018-05-13, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa0613e952f4, moduleTitle=J Viral Hepat：相比APRI和FIB-4，GPR在预测CHB患者肝纤维化不同程度方面表现更佳, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fa0613e952f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460256, encodeId=73251460256b1, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=J Gastroenterol Hepatol：sCD163和sMR与CHB患者的组织学炎症活动度和纤维化有关；抗病毒治疗后，两者水平均降低, objectType=article, longId=135179, objectId=35111351e931, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35111351e931, replyNumber=0, likeNumber=79, createdTime=2018-04-14, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35111351e931, moduleTitle=J Gastroenterol Hepatol：sCD163和sMR与CHB患者的组织学炎症活动度和纤维化有关；抗病毒治疗后，两者水平均降低, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=35111351e931)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460255, encodeId=b08a1460255ce, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=Aliment Pharmacol Ther：常规监测的CHB患者HCC检测失败的预测因素, objectType=article, longId=131795, objectId=ac91131e9558, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac91131e9558, replyNumber=0, likeNumber=97, createdTime=2018-03-09, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac91131e9558, moduleTitle=Aliment Pharmacol Ther：常规监测的CHB患者HCC检测失败的预测因素, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ac91131e9558)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460254, encodeId=fb661460254db, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=Eur J Gastroenterol Hepatol：轻度CHB和乙型肝炎肝硬化患者间，LSM与肝纤维化相关因子间的相关性有显著差异, objectType=article, longId=122305, objectId=0206122305fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0206122305fc, replyNumber=0, likeNumber=68, createdTime=2017-12-06, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0206122305fc, moduleTitle=Eur J Gastroenterol Hepatol：轻度CHB和乙型肝炎肝硬化患者间，LSM与肝纤维化相关因子间的相关性有显著差异, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0206122305fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460253, encodeId=f163146025353, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=Gut：CHB免疫耐受患者肝癌和死亡风险较高, objectType=article, longId=121389, objectId=2bad1213890e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bad1213890e, replyNumber=0, likeNumber=80, createdTime=2017-11-27, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bad1213890e, moduleTitle=Gut：CHB免疫耐受患者肝癌和死亡风险较高, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2bad1213890e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460252, encodeId=b05114602524c, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=Aliment Pharmacol Ther：CHB携带者：替诺福韦酯能显著降低血清脂蛋白水平, objectType=article, longId=111533, objectId=e95e11153323, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e95e11153323, replyNumber=0, likeNumber=83, createdTime=2017-09-02, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e95e11153323, moduleTitle=Aliment Pharmacol Ther：CHB携带者：替诺福韦酯能显著降低血清脂蛋白水平, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e95e11153323)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460251, encodeId=977714602514b, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=Aliment Pharmacol Ther：长期口服核苷（酸）类似物治疗CHB不增加癌症风险, objectType=article, longId=98206, objectId=1e3d982060e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e3d982060e, replyNumber=0, likeNumber=73, createdTime=2017-05-10, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e3d982060e, moduleTitle=Aliment Pharmacol Ther：长期口服核苷（酸）类似物治疗CHB不增加癌症风险, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1e3d982060e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460250, encodeId=ff5614602508e, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=临床治愈成为慢性乙型肝炎（CHB）治疗更高目标, objectType=article, longId=32963, objectId=97f2329631e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97f2329631e, replyNumber=0, likeNumber=68, createdTime=2014-04-09, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97f2329631e, moduleTitle=临床治愈成为慢性乙型肝炎（CHB）治疗更高目标, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=97f2329631e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460249, encodeId=90bd146024988, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=干扰素个体化治疗CHB新近进展, objectType=article, longId=9279, objectId=d28d92e992, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d28d92e992, replyNumber=0, likeNumber=88, createdTime=2012-08-25, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d28d92e992, moduleTitle=干扰素个体化治疗CHB新近进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d28d92e992)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460248, encodeId=9a791460248a0, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=高嘉宏教授：慢性乙型肝炎（CHB）的管理, objectType=article, longId=7242, objectId=9272e242a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9272e242a6, replyNumber=0, likeNumber=86, createdTime=2012-06-22, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9272e242a6, moduleTitle=高嘉宏教授：慢性乙型肝炎（CHB）的管理, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9272e242a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460247, encodeId=3606146024e09, content=<a href='/topic/show?id=360b458842' target=_blank style='color:#2F92EE;'>#CHB#</a>, objectTitle=陈成伟：CHB初治药物选择 [APASL 2012], objectType=article, longId=4292, objectId=19864292ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19864292ab, replyNumber=0, likeNumber=69, createdTime=2012-03-12, rootId=0, userName=cmj10wellington, userId=52416269929, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19864292ab, moduleTitle=陈成伟：CHB初治药物选择 [APASL 2012], moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=19864292ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

CHB

2020-05-29

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

Hepatology：乙肝纳米疫苗εPA-44可明显提高CHB患者的HBeAg血清学转换率

2021-08-20

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

J Hepatol：长期恩替卡韦/替诺福韦治疗CHB 生存率影响几何？

2018-06-29

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

Liver Int：在埃塞俄比亚CHB患者中，HDV感染很少见，但与更严重的肝纤维化相关

2018-06-26

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

Hepatol Res：在日本CHB患者中，早期从恩替卡韦治疗转换到聚乙二醇干扰素的序贯治疗，结果并不令人满意

2018-06-06

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

J Hepatol：接受核苷酸类似物治疗的CHB患者中，治疗后血清ALT达到正常水平，可较少肝脏相关事件。

2018-05-20

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

J Viral Hepat：相比APRI和FIB-4，GPR在预测CHB患者肝纤维化不同程度方面表现更佳

2018-05-13

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

J Gastroenterol Hepatol：sCD163和sMR与CHB患者的组织学炎症活动度和纤维化有关；抗病毒治疗后，两者水平均降低

2018-04-14

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

Aliment Pharmacol Ther：常规监测的CHB患者HCC检测失败的预测因素

2018-03-09

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

Eur J Gastroenterol Hepatol：轻度CHB和乙型肝炎肝硬化患者间，LSM与肝纤维化相关因子间的相关性有显著差异

2017-12-06

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

Gut：CHB免疫耐受患者肝癌和死亡风险较高

2017-11-27

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

Aliment Pharmacol Ther：CHB携带者：替诺福韦酯能显著降低血清脂蛋白水平

2017-09-02

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

Aliment Pharmacol Ther：长期口服核苷（酸）类似物治疗CHB不增加癌症风险

2017-05-10

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

临床治愈成为慢性乙型肝炎（CHB）治疗更高目标

2014-04-09

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

干扰素个体化治疗CHB新近进展

2012-08-25

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

高嘉宏教授：慢性乙型肝炎（CHB）的管理

2012-06-22

cmj10wellington (审核中...)

前往app查看评论内容

#CHB#

陈成伟：CHB初治药物选择 [APASL 2012]

2012-03-12

科室
- - 订阅+
  - 更多科室
工具
服务